Simple, sensitive, and visual detection of 12 respiratory pathogens with one‐pot‐RPA‐CRISPR/Cas12a assay

Author:

Tan Qi1ORCID,Shi Yaoqiang1,Duan Chenlu2,Li Qingyuan13,Gong Tao13,Li Shilin1,Duan Xiaoqiong1,Xie He4,Li Yujia1,Chen Limin145ORCID

Affiliation:

1. Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College Chengdu China

2. Sichuan Provincial Judicial Police General Hospital Chengdu China

3. North Sichuan Medical College Nanchong Sichuan China

4. The Hospital of Xidian Group Xi'an China

5. The Joint‐Laboratory on Transfusion‐Transmitted Diseases (TTDs) between Institute of Blood Transfusion and Nanning Blood Center, Nanning Blood Center Nanning China

Abstract

AbstractRespiratory infections pose a serious threat to global public health, underscoring the urgent need for rapid, accurate, and large‐scale diagnostic tools. In recent years, the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR‐associated) system, combined with isothermal amplification methods, has seen widespread application in nucleic acid testing (NAT). However, achieving a single‐tube reaction system containing all necessary components is challenging due to the competitive effects between recombinase polymerase amplification (RPA) and CRISPR/Cas reagents. Furthermore, to enable precision medicine, distinguishing between bacterial and viral infections is essential. Here, we have developed a novel NAT method, termed one‐pot‐RPA‐CRISPR/Cas12a, which combines RPA with CRISPR molecular diagnostic technology, enabling simultaneous detection of 12 common respiratory pathogens, including six bacteria and six viruses. RPA and CRISPR/Cas12a reactions are separated by paraffin, providing an independent platform for RPA reactions to generate sufficient target products before being mixed with the CRISPR/Cas12a system. Results can be visually observed under LED blue light. The sensitivity of the one‐pot‐RPA‐CRISPR/Cas12a method is 2.5 × 100 copies/μL plasmids, with no cross‐reaction with other bacteria or viruses. Additionally, the clinical utility was evaluated by testing clinical isolates of bacteria and virus throat swab samples, demonstrating favorable performance. Thus, our one‐pot‐RPA‐CRISPR/Cas12a method shows immense potential for accurate and large‐scale detection of 12 common respiratory pathogens in point‐of‐care testing.

Publisher

Wiley

Reference42 articles.

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

2. World Health Organization. Deaths by cause age sex by country and by region 2000‒2016 (2018). 2016.https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates

3. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

4. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID‐19: an evidence‐based clinical practice guideline (updated version);Jin YH;Mil Med Res,2020

5. Biochemical characterization of SARS-CoV-2 nucleocapsid protein

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3